Back to top
more

Chimerix (CMRX)

(Delayed Data from NSDQ)

$0.98 USD

0.98
118,734

-0.02 (-2.25%)

Updated May 15, 2024 04:00 PM ET

After-Market: $0.98 0.00 (0.26%) 4:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CMRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Chimerix, Inc. [CMRX]

Reports for Purchase

Showing records 81 - 100 ( 114 total )

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 81

03/31/2021

Company Report

Pages: 43

Initiating at OUTPERFORM; The Value Is Not a Chimera, Buy CMRX

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 82

03/25/2021

Daily Note

Pages: 3

BARDA Issues SSN for Smallpox Antivirals, the First Step in the RFP Process

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 83

02/25/2021

Company Report

Pages: 6

4Q20 Results; Strong Data From DSTAT in COVID-19 Trial Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 84

01/11/2021

Company Report

Pages: 8

Another Impressive Acquisition Announced; Raising PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 85

12/07/2020

Daily Note

Pages: 3

FDA Accepts NDA for Brincidofovir in Smallpox; PDUFA Date of April 7, 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 86

12/07/2020

Company Report

Pages: 3

FDA Accepts NDA for Brincidofovir in Smallpox; PDUFA Date of April 7, 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 87

11/05/2020

Company Report

Pages: 6

3Q20 Results; BCV in Smallpox Rolling NDA Submission Completed

Provider: H.C. Wainwright & Co., Inc.

Analyst: WRIGHT J

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 88

08/11/2020

Company Report

Pages: 6

2Q20 Results; Rolling NDA for BCV in Small Pox to Complete This Quarter

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 89

06/26/2020

Company Report

Pages: 8

Highlights From HCW Virtual Fireside Chat

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 90

05/07/2020

Company Report

Pages: 8

1Q20 Results; Catalysts in AML, COVID-19 and Smallpox in 2H20

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 91

04/29/2020

Company Report

Pages: 8

Chimerix Keeps Busy During the Pandemic With COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 92

04/29/2020

Company Report

Pages: 7

Brincidofovir Receives FDA Clearance for Rolling Submission of NDA for Smallpox

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 93

02/26/2020

Company Report

Pages: 8

4Q19 Results; DSTAT Phase 3 Study to Commence in Mid-2020; BCV NDA Submission Expected 2H20

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 94

01/29/2020

Daily Note

Pages: 4

Brincidofovir Smallpox Data Presented at the 2020 American Society for Microbiology Biothreats Meeting

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 95

12/10/2019

Daily Note

Pages: 3

Phase 2 DSTAT Presentation at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 96

11/06/2019

Company Report

Pages: 8

3Q19 Results; BCV NDA Filing for Smallpox Expected Mid-2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 97

10/01/2019

Daily Note

Pages: 3

Brincidofovir Exclusive Global Licensing Agreement With SymBio Pharmaceuticals Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 98

08/08/2019

Company Report

Pages: 8

2Q19 Results; Phase 3 CX-01 Trial Data in AML Possible Mid-2020; BCV NDA for Small Pox Filing Expected in 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 99

08/01/2019

Company Report

Pages: 7

Raising Our Price Target to $7 From $5 Due to the Acquisition of CX-01

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Chimerix, Inc.

Industry: Medical - Products

Record: 100

07/31/2019

Daily Note

Pages: 3

Entry Into Oncology: Chimerix Acquires an AML Drug

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party